Overview

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
Phase:
Phase 2
Details
Lead Sponsor:
Conatus Pharmaceuticals Inc.
Collaborator:
Idun Pharmaceuticals
Treatments:
Caspase Inhibitors